80090, 52874, 52880, 63497, and 33425 methods and compositions of human proteins and uses thereof
First Claim
1. An isolated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______;
b) a nucleic acid molecule comprising a fragment of at least 15 nucleotides of the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______;
c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or a complement thereof, under stringent conditions;
f) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______; and
g) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides isolated nucleic acids molecules, designated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, which encode novel fucosyltransferase, seven transmembrane receptor, or RhoGAP family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80090, 52874, 52880, 63497, or 33425 gene has been introduced or disrupted. The invention still further provides isolated 80090, 52874, 52880, 63497, or 33425 proteins, fusion proteins, antigenic peptides and anti-80090, 52874, 52880, 63497, or 33425 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
76 Citations
24 Claims
-
1. An isolated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecule selected from the group consisting of:
-
a) a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______;
b) a nucleic acid molecule comprising a fragment of at least 15 nucleotides of the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______;
c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______;
e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or a complement thereof, under stringent conditions;
f) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______; and
g) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______. - View Dependent Claims (2, 3, 6, 7, 8, 11, 12, 14, 15, 18, 19, 20, 21, 22, 23, 24)
-
-
4. An isolated 80090, 52874, 52880, 63497, or 33425 polypeptide selected from the group consisting of:
-
a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof;
b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO;
1, 3, 4, 6, 7, 9, 10, 12, 13 or 15, or a complement thereof under stringent conditions;
c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO;
2, 5, 8, 11 or 14; and
d) the amino acid sequence of SEQ ID NO;
2, 5, 8, 11 or 14. - View Dependent Claims (5, 9, 10, 13, 16)
-
-
17. A method for identifying a compound capable of treating a disorder characterized by aberrant 80090, 52874, 52880, 63497, or 33425 nucleic acid expression or 80090, 52874, 52880, 63497, or 33425 polypeptide activity comprising assaying the ability of the compound to modulate 80090, 52874, 52880, 63497, or 33425 nucleic acid expression or 80090, 52874, 52880, 63497, or 33425 polypeptide activity, thereby identifying a compound capable of treating a disorder characterized by aberrant 80090, 52874, 52880, 63497, or 33425 nucleic acid expression or 80090, 52874, 52880, 63497, or 33425 polypeptide activity.
Specification